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Abstract
Laminin a2( LAMA2)-deficient congenital muscular dystrophy is a severe, early-onset disease caused by abnormal levels of
laminin 211 in the basal lamina leading to muscle weakness, transient inflammation, muscle degeneration and impaired
mobility. In a Lama2-deficient mouse model for this disease, animal survival is improved by muscle-specific expression of
the apoptosis inhibitor Bcl-2, conferred by a MyoD-hBcl-2 transgene. Here we investigated early disease stages in this model
to determine initial pathological events and effects of Bcl-2 on their progression. Using quantitative immunohistological and
mRNA analyses we show that inflammation occurs very early in Lama2-deficient muscle, some aspects of which are reduced
or delayed by the MyoD-hBcl-2 transgene. mRNAs for innate immune response regulators, including multiple Toll-like
receptors (TLRs) and the inflammasome component NLRP3, are elevated in diseased muscle compared with age-matched
controls expressing Lama2. MyoD-hBcl-2 inhibits induction of TLR4, TLR6, TLR7, TLR8 and TLR9 in Lama2-deficient muscle
compared with non-transgenic controls, and leads to reduced infiltration of eosinophils, which are key death effector cells.
This congenital disease model provides a new paradigm for investigating cell death mechanisms during early stages of
pathogenesis, demonstrating that interactions exist between Bcl-2, a multifunctional regulator of cell survival, and the
innate immune response.
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Introduction
Muscular dystrophies are degenerative neuromuscular diseases
characterized by progressive loss of muscle structure and function
that impairs mobility, reduces quality of life, and can lead to early
lethality. There are at least 40 types of muscular dystrophies,
varying in onset and severity, which are caused by genetic changes
affecting proteins required for normal muscle function [1].
Congenital muscular dystrophies are early onset diseases with
muscle weakness occurring at or shortly after birth. They are
typically caused by abnormal expression of proteins required for
structural and signaling linkages between muscle cells and the
extracellular matrix surrounding them [2]. Laminin a2( LAMA2)-
deficient congenital muscular dystrophy (Muscular Dystrophy,
Congenital Merosin-deficient Type 1A, (MDC1A)) is a severe
form of this type of disease. Laminins are trimeric proteins
comprised of an a, b and c chain. Laminin-211 (a2b1c1o r
merosin) is normally the most prevalent form in the basal lamina
around muscle fibers [3]. Laminin-211 interacts with a-dystrogly-
can and a7b1 integrin on the muscle fiber, and integrity of these
interactions is critical for muscle function and survival. In
MDC1A, caused by insufficient levels of laminin a2 chain [4],
there is early onset weakness, a transient phase of inflammation,
loss of muscle fibers and poor muscle regeneration, leading to
irregular muscle fibers, fat deposition and fibrosis.
Degeneration of muscle in muscular dystrophies is typically
accompanied by inflammatory responses that can vary in
magnitude and temporal progression and play a significant role
in the physiology of the diseased muscle. As recently reviewed [5],
there is a dynamic relationship between skeletal muscle cells and
cells of the immune system, which routinely survey tissues for
abnormalities, respond quickly to destroy and remove damaged
elements and promote muscle repair.
Using a Lama2-deficient mouse model (Lama2
dy-W [6]), we found
that expression of the proinflammatory cytokines TNFa and IL-1b
is elevated in Lama2-mutant muscles within 7 days after birth, prior
to widespread muscle degeneration [7]. Lama2-deficient muscle
also had increased expression of tenascin C (TN-C), a matrix
glycoprotein upregulated in pathological conditions such as
inflammation, as well as reduced expression of lymphatic vessel
endothelial hyaluronan receptor-1 (LYVE-1) in lymphatic capil-
laries within the muscles [7]. LYVE-1 is specifically found in
lymphatic endothelial cells and is rapidly degraded when these
cells are exposed to TNFa [8], therefore changes in both TN-C
and LYVE-1 could result from elevated inflammatory cytokines
present in 7 day-old Lama2-deficient muscles. Between 7 and 14
days of age, inflammation in Lama2-deficient mouse muscle is
accompanied by apoptotic and necrotic fiber degeneration. These
features in the mouse model correlate with the early, transient
inflammation and fiber degeneration in human MDC1A
[9,10,11].
Accumulating evidence indicates that ‘presymptomatic’ activa-
tion of inflammatory pathways is a common feature of other, later-
onset forms of muscular dystrophy as well, including those caused
by deficiencies in dysferlin or dystrophin [12,13]. The mechanisms
through which defects in muscle structure lead to activation of
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however, that this process involves regulation of the innate
immune system, which is poised to quickly respond to abnormal
macromolecules within damaged tissue. The Lama2-deficient
mouse model, with its early-onset inflammation, provides an ideal
system to study the role of the innate immune pathways in muscle
pathogenesis.
The innate immune response is an inherent mechanism,
functional at birth, which protects organisms from pathogens. It
also plays a broader role in pathologies related to endogenous
tissue damage, inflammation and autoimmune diseases [14]. One
general mechanism of innate immunity relies on recognition of
aberrant molecular patterns within diseased or damaged tissues.
Molecules with pathogen-associated molecular patterns (PAMPs)
(from microorganisms) or damage-associated molecular patterns
(DAMPs) (from endogenous tissues) are recognized by specific
receptors on immune system cells (e.g. macrophages) such as Toll-
like receptors (TLRs) [15,16]. Upon binding to DAMP/PAMP
ligands, TLRs induce NF-kb activation and subsequent TNFa
and pro-IL-1b synthesis. IL-1b release from cells requires
additional pro-IL-1b processing by caspase-1, which occurs within
multi-component inflammasome complexes containing the ‘‘nu-
cleotide-binding domain leucine-rich repeat containing’’ receptor
(NLR) protein NLRP3 [17]. NLRP3 (NALP3, cryopyrin) is critical
for propagation of innate inflammatory signals. These innate
pathways contribute significantly to the development of inflam-
matory disorders [16], kidney disease [15], and metabolic diseases
[17], and inflammasome components are upregulated in dysferlin-
deficient muscular dystrophy [18].
There are at least 13 mammalian TLRs that recognize
numerous specific DAMP/PAMP ligands to promote inflamma-
tion in damaged tissues [14,15]. DAMP ligands [and respective
TLRs] include hyaluronan fragments, heat shock proteins (HSPs),
High Mobility Group Box 1 Protein (HMGB1), biglycan, uric
acid, lipoproteins [TLR2 or TLR4], mRNA, double-stranded
RNA [TLR3], fibrinogen, heparan sulfate, fibronectin [TLR4],
single-stranded RNA [TLR7 or TLR8], and unmethylated CpG
motif DNA [TLR9]. TLR1 and TLR6 act as dimers with TLR2.
Some TLRs (e.g. TLR1, TLR2, TLR4, TLR6) are localized at the
plasma membrane and recognize extracellular ligands, while
others (TLR3, TLR7, TLR8, TLR9) are intracellular receptors,
associated with endoplasmic reticulum (ER) and endosome
membranes and recognize intracellular ligands.
In previous studies using Lama2-deficient mice, we found that
muscle-specific overexpression of the apoptosis inhibitor Bcl-2 (via
MyoD-hBcl-2 or MRF4-hBcl-2 transgenes) or systemic inactiva-
tion of the pro-apoptotic protein Bax (using Bax
2/2 mice)
improved animal size and survival [19,20], demonstrating that
altering expression of intrinsic apoptosis pathway regulators can
dramatically affect long term pathology. We sought to determine
whether altering Bcl-2 levels could also modulate the earliest
events in pathogenesis, focusing on the early inflammation in this
disease and elements of innate immunity.
Here we report that specific elements of the innate immune
response are significantly induced in 7 day-old Lama2-deficient
muscles. These include mRNAs for TLR1, TLR2, TLR4, TLR6,
TLR7, TLR8, TLR9, and NLRP3, along with increased
eosinophil infiltration and eotaxin-1 expression. Muscle-specific
Bcl-2 expression reduces the initial expression of TN-C in Lama2-
deficient muscles, while some other indices of pathology
(macrophage/neutrophil/monocyte infiltration, LYVE-1 expres-
sion) are not affected. Moreover, muscle-specific Bcl-2 expression
significantly inhibits the induction of TLR4, TLR6, TLR7, TLR8,
and TLR9 and reduces eosinophil infiltration. Together, our data
demonstrate that specific regulators of the innate immune
response are induced in neonatal muscles as a consequence of
the disruption in normal muscle cell-extracellular matrix interac-
tions, and this process can be modulated by Bcl-2.
Materials and Methods
Animals
All procedures involving mice were approved by the Boston
Biomedical Research Institute Animal Care and Use Committee
(permit number 01-07) and followed guidelines of the US Public
Health Service Policy on Humane Care and Use of Laboratory
Animals and the USDA Animal Welfare Act. Wild-type C57BL/
6J mice (Jackson Laboratories, Bar Harbor, ME, USA), Lama2-
deficient mice (Lama2
dy-W) with a targeted lacZ insertion disrupting
normal laminin a2 expression [6], and MyoD-hBcl-2 transgenic
mice that overexpress human Bcl-2 specifically in skeletal muscles,
driven by a mouse MyoD promoter [19,20], were maintained in a
pathogen-free, temperature controlled environment. Lama2-defi-
cient mice were generated by interbreeding heterozygotes
(Lama2
+/2) because of early lethality in Lama2
2/2 animals. To
generate Lama2
2/2 mice that carried the MyoD-hBcl-2 transgene,
Lama2
+/2 mice were bred with transgenic MyoD-hBcl-2 mice to
generate F1 progeny that were Lama2
+/2; MyoD-hBcl-2
+/2. These
Lama2
+/2; MyoD-hBcl-2
+/2 mice were then bred to Lama2
+/2 mice
to generate the F2 progeny used in these experiments. In this way,
all Lama2
+/+, +/2 or 2/2 animals used in experiments involving the
MyoD-hBcl-2 transgene were from the F2 generation and carried
either a single copy of the transgene or no transgene. Mice were
genotyped using PCR as described [20].
Muscle samples for RNA or protein analysis were collected at
various ages and immediately snap frozen on dry ice. Upper
hindlimb muscle samples included all muscles surrounding femur
except the quadriceps. For immunohistological analyses, muscles
or intact lower hindlimbs were embedded in O.C.T. freezing
compound (Tissue-Tek, Sakura-Finetek, Torrence, CA, USA),
then quickly frozen in isopentane chilled with liquid nitrogen.
Immunostaining and TUNEL staining
Frozen tissues were cryosectioned (10 mm sections) and
immunostained to analyze protein expression as described [7].
Primary antibodies used were rat anti-mouse TN-C (diluted 1/
500, clone MTn-12, T3413, Sigma, St. Louis, MO, USA,), rabbit
anti-mouse LYVE-1 (1/500, 14917, Abcam, Cambridge, MA,
USA), rat anti-mouse major basic protein (MBP) (1/1000, clone
MT-14-7-3, from J.J. Lee, Mayo Clinic) and Alexa Fluor 488-
labeled rat anti-mouse CD11b (1/500, M1/70, 557672, BD
Pharmingen, San Diego, CA, USA). Secondary antibodies used
were Alexa Fluor 488 goat anti-rabbit IgG (1/1000, A11070)),
Alexa Fluor 594 goat anti-rabbit IgG (1/1000, A11072), Alexa
Fluor 546 goat anti-mouse IgG (1/1000, A11018,) all from
Invitrogen (Carlsbad, CA, USA) and Cy3 goat anti-rat IgG (1/
2000, 112-165-006, Jackson Immunoresearch, West Grove, PA,
USA).
TUNEL assays were used to identify apoptotic cells in muscle
tissue. Lower hindlimbs sections were fixed with 4% paraformal-
dehyde and TUNEL stained using an In Situ Cell Death
Detection Kit (Roche Applied Science, Indianapolis, IN, USA)
following the manufacturer’s protocol. TUNEL stained samples
were then immunostained to identify the sarcolemma or basal
lamina in order to distinguish apoptotic nuclei associated with
muscle fibers from non-muscle nuclei in the interstitial space. For 7
day-old muscles, rabbit anti-human dystrophin (diluted 1/1000,
15277 Abcam, Cambridge, MA, USA) was used to label the
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significant loss of dystrophin expression from diseased muscle
membranes. Therefore rabbit anti-mouse (pan)-laminin, (1/100,
L9393, Sigma, St. Louis, MO, USA), which recognizes other
laminin isoforms present in Lama2-deficient muscle, was used to
label the basal lamina around fibers. Appropriate Alexa Fluor 488
or 594 secondary antibodies (above) were used to visualize the
muscle fiber-associated antigens and to distinguish TUNEL(+)
nuclei within or outside of muscle fibers. Muscles in the TA/EDL
and gastrocnemius/soleus regions of each limb were imaged and
the number of TUNEL(+) cells within and outside of the basal
lamina or sarcolemma were quantified.
Samples were imaged using a Leica DMR microscope and
imaging system with Leica IM50 Image Manager software. Minor
linear brightness and contrast adjustments were made to some
images using Adobe Photoshop, with adjustments applied to the
entire image and equivalently applied to each sample within an
experimental set. Morphometric analysis of antigen expression was
done using NIH Image J software.
Western Blot Analysis
Proteins were extracted from frozen muscle samples and protein
was analyzed on western blots as previously described [20] (10–
50 mg protein/lane, equal amounts loaded/lane on each blot).
Antibodies used were: rabbit anti-human Apaf-1 (apoptotic
protease-activating factor-1, diluted 1/1000, AB16941, Chemicon,
Billerica, MA, USA), rabbit anti-human XIAP (X-linked inhibitor
of apoptosis, 1/1000, 2042, Cell Signaling Technology, Danvers,
MA, USA), rabbit anti-human FLIP (FLICE-inhibitory protein,
1/1000, ab8421, Abcam, Cambridge, MA, USA), and rabbit anti-
human ARC (apoptosis repressor with caspase recruitment
domain, 1/1000, 160737, Cayman Chemical, Ann Arbor, MI,
USA). Each blot was simultaneously probed with mouse anti-
rabbit GAPDH (1/1000, 10R-G109a, Fitzgerald, Acton, MA,
USA) for normalization of protein loading. Secondary antibodies
used for detection were Alexa Fluor 680 goat anti- rabbit IgG (1/
10,000, A21109, Invitrogen, Carlsbad, CA, USA) and IRDye 800
goat-anti mouse IgG (1/10,000, 610-132-121, Rockland, Gilberts-
ville, PA, USA). Blots were scanned using a LI-COR Odyssey
Infrared Imaging System to visualize protein expression.
RNA Expression
RNA was extracted from frozen muscle tissues, treated with
DNAse as described [7] then reverse transcribed using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA, USA) following the manufacturer’s protocol.
Resultant cDNAs were analyzed by quantitative PCR (QPCR)
using triplet reactions per sample. Eotaxin-1 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were analyzed in TaqMan
probe QPCR assays as described [7], using the following primer/
probe sets (listed 59-39): eotaxin-1 (CCL11, NM_011330) forward
TCAAGACCAGGTTGGGCAAAGA, reverse GGTTAGTGT-
CAAGAGAGGAGGTT, probe 59FAM- AAGAAGTGGGTC-
CAGGATGCCACAAA-39TAMRA; GAPDH (NM_008084.2)
forward TGTGTCCGTCGTGGATCTGA, reverse CCTGC-
TTCACCACCTTCTTGA, probe 59FAM-CCTGGAGAAACC-
TGCCAAGTATGA-39TAMRA. SYBR Green QPCR assays
(DyNAmo HS SYBR Green Q-PCR Kit, Finnzymes/Thermo-
Fisher, Waltham, MA, USA) were used for other genes (primers in
Table 1) using the following PCR conditions: 95uC 15 min., 45
cycles of (94uC 10 sec., 60uC 30 sec., 72uC 30 sec.), 72uC 5 min.,
followed by a 65uC–95uC melt curve to confirm the amplification
of single products for each reaction. Separate reactions without
reverse transcriptase confirmed that RNA samples did not contain
DNA that interfered with the PCR analysis. Relative mRNA
levels, expressed relative to a normal wild-type sample within each
data set, were calculated after normalizing to GAPDH levels in
each sample.
Statistics
Statistical significance was calculated using unpaired t-tests, or
nonparametric Mann-Whitney tests and Prism 4.0c statistical
analysis software (GraphPad Software, La Jolla, CA, USA). All
data presented are mean values 6 SEM. All statistically significant
differences in data values are noted (*) as described in figure
legends.
Results
Muscle-specific Bcl-2 expression reduces early expression
of TN-C in Lama2-deficient muscle
Early pathology in mice with Lama2-deficient muscular
dystrophy is marked by increased expression of TN-C in the
extracellular matrix around muscle fibers, and decreased expres-
sion of LYVE-1 in lymphatic capillaries within the muscles [7]. We
bred Lama2
+/2 mice with MyoD-hBcl-2 transgenic mice that
express human Bcl-2 specifically in skeletal muscle as done
previously [19,20] to determine the effects of muscle-specific Bcl-2
Table 1. Primers Used for SYBR Green Quantitative RT-PCR Assays.
Gene
Accession
Number Forward Primer (59 –3 9) Reverse Primer (59-3 9)
Amplicon
Size (bp)
Primer Spans Exon
Junction
TLR1 NM_030682.1 CCGTGATGCACAGCTCCTTGGTT GGGTATAGGACGTTTCTGTAGGGGT 109 Yes - Reverse
TLR2 NM_011905.3 CTAGGCTGGTGCCCAGATGGCTAG CCTGCCCGGAGCCTAGGAGTC 70 Yes - Reverse
TLR3 NM_126166.4 TAAAGAGTTCTCCCCGGGGTGTTTCC GGTGGGGGTTCAGTTGGGCG 83 Yes- Forward
TRR4 NM_021297.2 CCCTGCATAGAGGTAGTTCC GCCATGCCATGCCTTGTCTTCA 219 Yes - Forward
TLR6 NM_011604.3 ACCGTCAGTGCTGGAAATAGAGCTT AGGCCAGGGCGCAAACAAAGT 142 Yes - Forward
TLR7 NM_133211.3 AGGCTCTGCGAGTCTCGGTT GGAGCCAAGGACATCTTTCTTGAAGGC 99 Yes - Reverse
TLR8 NM_133212.2 GAACATGGAAAACATGCCCCTCA TGCAATCACAAGGGAGTTGTGCCT 145 Yes - Forward
TLR9 NM_031178.2 CTGAGAGACCCTGGTGTGGAACA CGACGGAGAACCATGTTGGGAGA 96 Yes - Reverse
NLRP3 NM_145827.3 TGCCTGTTCTTCCAGACTGGTGA CACAGCACCCTCATGCCCGG 144 Yes - Forward
GAPDH NM_008084.2 ACCCAGAAGACTGTGGATGG CACATTGGGGGTAGGAACAC 170 No
doi:10.1371/journal.pone.0022369.t001
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ogy one to two weeks after birth. At 7 days of age, MyoD-hBcl-2
transgenic mice that express Lama2 (Lama2(+): Lama2
+/+ or
Lama2
+/2) had minimal levels of TN-C in the matrix around
fibers, and normal levels of LYVE-1 in the numerous lymphatic
capillaries present within the muscle bed (Figures 1A, B, M, N, O)
similar to normal patterns observed previously in non-transgenic
Lama2(+) at this age [7]. Quantitative analysis determined that
MyoD-hBcl-2 expression did not affect expression of these markers
in Lama2(+) muscles (Figures 1G, H). TN-C expression was
markedly increased in Lama2(2) (Lama2
2/2) muscles at this age
(Figure 1C). However, MyoD-hBcl-2 transgenic Lama2(2) mice
expressed significantly less TN-C than non-transgenic cohorts
(Figures 1E, I), indicating that signals driving its expression,
perhaps related to inflammation, were reduced by Bcl-2
expression. This effect was transient however, and by 14 days of
age, MyoD-hBcl-2 transgenic Lama2(2) muscle also expressed
significant levels of TN-C (Figure 1K), affecting most of the
muscles within the limb. Consistent with previous results [7],
LYVE-1 expression was reduced in lymphatic endothelial cells
within Lama2(2) muscle tissues, but unlike TN-C expression, this
was not affected by MyoD-hBcl-2 expression at 7 days of age
(Figures 1D, F, J,Q). Higher magnification images of these samples
(Figures 1M–1R) show that, as previously reported [7], a broader
area of muscle had reduced LYVE-1 expression as compared with
elevated TN-C expression. LYVE-1 expression was slightly higher
in transgenic Lama2(2) muscle tissue at 14 days of age (Figure 1L).
Thus not all aspects of early pathology that could be affected by
inflammation were reduced by muscle-specific Bcl-2 transgene
expression.
Muscle-specific Bcl-2 effects on prevalence of apoptotic
cells, apoptosis regulators and inflammatory cell
infiltration
We examined 7 and 14 day-old muscle for other aspects of
pathology, including markers of apoptosis and inflammation. Only
a small number of apoptotic (TUNEL(+)) cells were present in
Lama2(2) limb muscles at 7 days of age (Figure 2A), and these
were mostly interstitial cells and not myofibers. The MyoD-hBcl-2
transgene did not significantly affect the number of TUNEL(+)
cells. However, of the few TUNEL(+) cells present, there was a
trend in MyoD-hBcl-2 transgenic mice for fewer to be myofiber
cells than interstitial cells when compared with non-transgenic
Lama2(2) mice at this age. For example, 38% of the 7 day-old
Lama2(2) gastrocnemius/soleus and TA muscle regions examined
(n=8 from 4 mice) had some TUNEL(+) myofibers, while only
22% of the cohort MyoD-hBcl-2 transgenic Lama2(2) muscles
(n=9 from 5 mice) contained TUNEL(+) myofibers. The
proportion of the TUNEL(+) cells that were myofibers in these
muscles is shown in Figure 2B. At 14 days of age, TUNEL(+) cells
were more abundant in both transgenic and non-transgenic
Lama2(2) muscles, and there was no difference in the total
number due to the MyoD-hBcl-2 transgene. At 14 days, all of the
Lama2(2) muscles examined contained some TUNEL(+) myofi-
bers, however, there was a higher proportion of TUNEL(+)
myofibers in MyoD-hBcl-2 transgenic than non-transgenic
Lama2(2) cohorts (Figures 2A, B). Together, these data are
consistent with a delay in initial myofiber apoptosis due to Bcl-2
transgene expression. Here, delayed apoptosis would lead to a
lower proportion of TUNEL(+) myofibers in transgenic muscle at
7 days compared with non-transgenic muscle. At 14 days, a higher
proportion of TUNEL(+) fibers would be expected in the
transgenic tissue as apoptosis progressed, while non-transgenic
muscles at 14 days would have proceeded to later events of
degeneration and regeneration. Since the Bcl-2 expression was
restricted to muscle, no direct effect of the transgene on non-
muscle cell apoptosis progression would be expected.
Consistent with prior observations of inflammation in early
Lama2-deficient muscle pathology [7], we found significant
infiltration of CD11b(+) inflammatory cells (macrophages, neu-
trophils, monocytes) in Lama2(2) muscles at both 7 and 14 days.
The MyoD-hBcl-2 transgene did not significantly affect the
prevalence of CD11b(+) cells at either age (Figure 2C), indicating
that inflammatory signals that promote the chemotactic migration
of this group of cells were active and not affected by Bcl-2
expression in the muscle cells.
We examined the expression of several other regulators of
apoptosis in these muscles by western blot analysis. The anti-
apoptotic proteins ARC, XIAP, or FLIPL, and the pro-apoptotic
factor Apaf-1 were each present in Lama2(+) and Lama2(2) muscle
and could contribute to muscle survival, but there were no
differences in their expression among any of the muscles examined
(Figure 3). One exception was the 22 kDa form of FLIP, which
was expressed at similar levels in all 7 day-old tissues, then was
down regulated in 13 day-old Lama2(+) muscle while remaining at
higher levels in Lama2(2) muscles (Figure 3D). p22-FLIP is a
procaspase-8 cleavage product of FLIP that inhibits extrinsic
CD95 and TRAIL-induced cell death in immune system cells, but
also promotes NF-kb activation and T cell proliferation [21]. High
p22-FLIP levels in day 13 Lama2
2/2 muscles might reflect either
the presence of proliferating myoblasts participating in muscle
regeneration at this age or a role in inhibiting pathology via
CD95/TRAIL mechanisms. The Bcl-2 transgene had no effect on
its expression.
Several TLRs are induced early in Lama2-deficient muscle
pathogenesis
Our observations that markers of inflammation were elevated
within a week after birth suggested that innate immunity
mechanisms were activated very early in Lama2-deficient muscle
disease progression. TLRs are known to function in innate
immunity pathways, responding to endogenous pathology-associ-
ated ligands as well as exogenous pathogens. We first examined
the expression of several TLRs in the Lama2
dy-W parental line at 7
days of age and found that mRNA levels for TLR2, TLR4, TLR6,
TLR7 and TLR8, and the inflammasome protein NLRP3 were all
significantly higher in upper hindlimb muscles of Lama2-deficient
mice compared with Lama2(+) cohorts. TLR3 expression,
however, was unaffected (Figure 4).
Muscle-specific Bcl-2 inhibits the induction of TLR
expression in early Lama2-deficient muscle pathogenesis
We compared TLR expression in 7 day-old gastrocnemius/
soleus muscles from cohorts of MyoD-hBcl-2 transgenic and non-
transgenic Lama2(2) mice and accompanying Lama2(+) controls,
all derived by breeding Lama2
dy-Wwith MyoD-hBcl-2 transgenic
mice. As observed in Lama2
dy-W upper hindlimb muscles, mRNAs
for NLRP3 and all TLRs (additionally including TLR1 and
TLR9) except TLR3 were elevated in Lama2(2) gastrocnemius/
soleus muscles relative to Lama2(+) muscles. These differences in
mRNA expression were therefore consistently observed in two
different groups of leg muscles and in both the parental mutant
Lama2
dy-W mice and mice derived by interbreeding them with the
MyoD-hBcl-2 transgenic line. Interestingly, MyoD-hBcl-2 trans-
gene expression in Lama2(2) mice resulted in significantly lower
levels of TLR4, TLR6, TLR7, TLR8 and TLR9 mRNA
(Figure 5). TLR1 was also reduced but not quite to a significant
Bcl-2 Inhibits Innate Immune Response in Muscle
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were immunostained with antibodies to TN-C (A, C, E) and LYVE-1 (B, D, F). (A) MyoD-hBcl-2 transgenic Lama2
+/2 mice had strong staining of
epimysium and tendons but negligible levels of TN-C around muscle fibers, similar to non-transgenic normal mice at this age. (C) TN-C expression
was elevated around Lama2
2/2 muscle fibers, but this was reduced in MyoD-hBcl-2 transgenic Lama2
2/2 muscles (E). (B) Lama2
+/2; MyoD-hBcl-2
+/2
mice had a normal punctate pattern of LYVE-1 expression, marking lymphatic capillaries within the muscle bed and interstitium as in non-transgenic
normal mice. (D) LYVE-1-expression was reduced in capillaries within the muscle bed of Lama2
2/2 mice, and this was not affected by the MyoD-hBcl-
2 transgene at 7 days of age (F). (G and H) Quantitation of TN-C and LYVE-1 expression in 7 day-old Lama2-expressing (Lama2(+): Lama2
+/+ or +/2)
muscle either with or without MyoD-hBcl-2 transgene showed there was no effect of transgene on these markers in normal muscle (n=4–5, p.0.05).
(I and J) Quantitation of TN-C and LYVE-1 expression in 7 day-old Lama2(+) and Lama2(2) (Lama2
2/2) muscle with or without MyoD-hBcl-2
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in TLR2, TLR3 or NLRP3. The effect of muscle-specific Bcl-2
expression was greatest on TLR4, TLR7 and TLR8, as their
mRNA levels in MyoD-hBcl-2 transgenic Lama2(2) muscles
remained comparable to those in Lama2(+) muscles.
Muscle-specific Bcl-2 reduces eosinophil infiltration in
Lama2-deficient muscles
In order to further address the impact of MyoD-hBcl-2
transgene expression on the innate immune response, we
examined the levels of eosinophil infiltration in muscles from
these 7 day-old mice. Eosinophils are key death-effector cells of
innate immune pathways, responding particularly to TLR7-
induced proinflammatory signals and drawn to damaged tissues
by chemoattractants such as eotaxin-1 (CCL11), a primary
chemokine for this cell type. Using wild-type primary myogenic
cell cultures, we found that eotaxin-1 mRNA is induced more than
12-fold in differentiated myotubes (but not proliferating myoblasts)
treated with the proinflammatory cytokine IFN-c, and to a smaller
degree by IL-4 and IL-6 (Supporting Figure S1, Methods S1).
Therefore, differentiated muscle cells can respond to inflammatory
cues (e.g. IFN-c) by synthesizing eotaxin-1, which in vivo could
promote eosinophil chemotaxis.
At 7 days of age, significant numbers of eosinophils were present
in Lama2(2) muscles, with few, if any, in Lama2(+) muscles
(Figures 6A, B, D, E, G). MyoD-hBcl-2 transgene expression
significantly reduced eosinophil numbers in Lama2(2) gastrocne-
mius/soleus muscles (Figures 6B, C, G). A similar trend was
observed in tibialis anterior/extensor digitorum longus (TA/EDL)
muscles (Figures 6E, F, G) but did not reach statistical significance.
This was likely due to higher variability in this region associated
with small foci with a high eosinophil density observed in several
samples, both with and without the transgene (Figure 6E, arrow).
Eotaxin-1 mRNA levels were also elevated in Lama2(2) muscles
relative to Lama2(+) muscles (Figure 6H). Less induction of
eotaxin-1 occurred in MyoD-hBcl-2 transgenic Lama2(2) muscles,
and differences in expression between these and Lama2(+) muscles
were not significant. Together, these data indicated that muscle-
specific expression of Bcl-2 could inhibit synthesis of specific
TLRs, chemokine expression (eotaxin-1), and functionally inhibit
infiltration of the innate death effector cells (eosinophils) in these
diseased neonatal muscles.
Discussion
Inflammation is an early feature of Lama2-deficient muscle,
evident by induction of TNFa and IL-1b, elevated TN-C around
muscle fibers, inflammatory cell (e.g. macrophage) infiltration and
loss of LYVE-1 [7]. Death mechanisms related to the proin-
flammatory environment present within a week after birth could
play a prominent role in the initial muscle loss in this disease. It is
therefore important to understand the mechanisms that initiate
inflammation in this neonatal period and factors that regulate its
progression.
Our data show that some, but not all, of the markers of pathology
were reduced in the earliest stages of Lama2-deficient disease
progression as a result of MyoD-hBcl-2 transgene expression. For
example,TN-CwasreducedintransgenicLama2-deficientmiceat7
days of age relative to non-transgenic cohorts, but TN-C expression
wasonlydelayed, and by 2 weeks no Bcl-2 effects were evident. This
muscle-specific Bcl-2 transgene had no effect on the loss of LYVE-1
in vessels within 7 day-old muscle (which likely reflects the presence
of a proinflammatory environment based on the sensitivity of this
protein to TNFa levels) or the prevalence of CD11b(+) cells
(macrophages, neutrophils, monocytes) at either 7 or 14 days. The
overall prevalence of apoptotic (TUNEL(+)) cells was also
unaffected by the Bcl-2 transgene, although most of these were
not muscle cells, and data are consistent with a delay in muscle cell
apoptosis in the MyoD-hBcl-2 transgenic compared with non-
transgenic Lama2-deficient mice.
We show that regulators of innate immunity are induced in
these diseased muscles within 7 days after birth, including TLR1,
transgene (n=7–9). (K and L) Quantitation of TN-C and LYVE-1 in 14 day-old muscles (n=3–4) (* p,0.03, ** p,0.001). (M–R) Higher magnification
images of muscle samples show that reduced LYVE-1 expression occurs more broadly throughout the muscle bed of Lama2-deficient mice than
elevated expression of TN-C. (M, N) MyoD-hBcl-2 transgenic Lama2
+/2 muscle in panels 1A and 1B showing normal expression of TN-C and LYVE-1,
respectively. (P, Q) MyoD-hBcl-2 transgenic Lama2
2/2 muscle in panels 1E, and 1F, showing elevated TN-C and reduced LYVE-1 staining. (O) and (R)
are merged images. (Scale bars in all images: 100 mM, T: tibia).
doi:10.1371/journal.pone.0022369.g001
Figure 2. Effects of MyoD-hBcl-2 on the prevalence of apoptotic and inflammatory cells in Lama2-deficient muscles. (A) Lower
hindlimb muscles from 7 and 14 day-old mice were TUNEL stained to detect apoptotic nuclei within muscle tissues (Lama2(+): Lama2
+/+ or +/2,
Lama2(2): Lama2
2/2). There were no TUNEL(+) cells in Lama2(+) muscle at 7 days (n=2 mice) and few in Lama2-deficient muscle (n=4 or 5 mice,
Lama2(2) without or with transgene respectively), but these increased in number by 14 days, and the MyoD-hBcl-2 transgene did not affect this
(n=5–8 mice). (B) These samples were additionally immunostained to distinguish apoptotic muscle cells (nuclei within the basal lamina or
sarcolemma) from interstitial cells. Of the few apoptotic cells present in Lama2(2) tissue at 7 days, there was a trend that fewer were muscle cells in
the MyoD-hBcl-2 transgenic tissue, but at 14 days, significantly higher proportions of the apoptotic cells in transgenic tissue were muscle cells. (C)
CD11b(+) cells (macrophages, neutrophils, monocytes) were present in Lama2-deficient quadricep muscles at both 7 and 14 days and MyoD-hBcl-2
transgene did not affect their prevalence. (n=3–7 mice, *p,0.04, **p,0.003).
doi:10.1371/journal.pone.0022369.g002
Bcl-2 Inhibits Innate Immune Response in Muscle
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22369Figure 3. Expression of apoptosis regulators in Lama2-deficient muscle. Upper hindlimb muscle proteins from mice of the indicated
genotypes and ages were analyzed on western blots probed with antibodies specific to (A) ARC, (B) XIAP, (C) Apaf-1, or (D) FLIP. Each blot was also
probed with antibodies to GAPDH to normalize for protein loading. ARC, XIAP and Apaf-1, and the 58 kDa FLIP isoform (FLIPL, a predominant anti-
apoptotic isoform) were present in all muscle samples with no differences associated with Lama2-deficiency or the MyoD-hBcl-2 transgene at these
ages. The isoform p22-FLIP was expressed in all 7 day-old muscles, but was reduced in Lama2(+) muscles at 13 days. Lama2(2) muscles maintained a
higher level of p22-FLIP at 13 days, and this was not affected by MyoD-hBcl-2 transgene expression.
doi:10.1371/journal.pone.0022369.g003
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22369Figure 4. Expression of TLRs and NLRP3 mRNA in 7 day-old Lama2-deficient muscles. RNA from upper hindlimb muscles of Lama2
dy-W
mice was analyzed by quantitative RT-PCR. Lama2(2) muscles expressed significantly higher levels of TLR2, TLR4, TLR6, TLR7, TLR8 and NRLP3 than
Lama2(+) muscles, while TLR3 was not affected by the absence of Lama2. (n=4, *p,0.016, **p,0.001).
doi:10.1371/journal.pone.0022369.g004
Figure 5. Effects of MyoD-hBcl-2 on expression of TLRs and NLRP3 mRNA in 7 day-old Lama2-deficient muscles. RNA from pooled
gastrocnemius/soleus muscles was analyzed by quantitative RT-PCR. All TLRs except TLR3, along with NLRP3 were induced in Lama2(2) muscles
relative to levels in Lama2(+) muscles. MyoD-hBcl-2 transgene expression inhibited the induction of TLR4, TLR6, TLR7, TLR8 and TLR9. (n=5–8,
*p,0.05, **p,0.008, ***p,0.0005).
doi:10.1371/journal.pone.0022369.g005
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22369TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, and NLRP3 but not
TLR3. Muscle-specific expression of Bcl-2, conferred by a MyoD-
hBcl-2 transgene that enhances Lama2-deficient mouse long-term
survival [19,20], also affects some of the earliest aspects of disease
progression. This includes the novel observation that Bcl-2
expression in Lama2-deficient muscle cells inhibits the induction of
TLR4, TLR6, TLR7, TLR8 and TLR9, and also reduces the
infiltration of eosinophils, which are key death effector cells.
Therefore, one or more of the molecular functions of Bcl-2 interact
with mechanisms that promote the innate immune response to
tissue damage. This early-onset congenital disease model serves as a
useful system in which to define these interactions.
Inadditiontomacrophagesand otherimmunesystemcellswhere
they are best studied, TLRs are also expressed in other cells types.
For example, TLR2, TLR4, TLR5 and TLR9 mRNAs are
expressed in normal muscle tissue [22]. TLR3 and TLR7 are
elevated in inflammatory myopathies [23,24] as is TLR7 in muscles
of Duchenne muscular dystrophy patients [25]. Cultured muscle
cells also express mRNAs for TLRs 1–7 and TLR9, and respond to
TLR ligands to activate NF-kb and produce chemokines
[22,23,24,26]. Therefore, the elevated levels of TLR and NLRP3
mRNA we observed in Lama2-deficient muscles could reflect gene
induction either in inflammatory cells (e.g. macrophages) within the
tissue or in the muscle cells themselves. Since muscle-specific
expression of Bcl-2 resulting from the MyoD-hBcl-2 transgene can
prevent the induction of TLR4, TLR6, TLR7, TLR8 and TLR9 in
Lama2-defient muscle, at least some of these gene expression
changes likely occur within the diseased muscle cells themselves.
Figure 6. Effects of MyoD-hBcl-2 on eosinophil infiltration and eotaxin-1 expression in 7 day-old Lama2-deficient muscles. (A–F)
Lower hindlimb muscles were immunostained for MBP-1 expression, a marker for eosinophils. Shown are the gastrocnemius/soleus (A–C) and TA/
EDL (D–F) regions from mice of the genotypes indicated. Eosinophil infiltration was evident in Lama2(2) muscles, and this was reduced in
Lama2(2);MyoD-hBcl-2(+) muscles. Arrow indicates a focal cluster of eosinophils often observed in this region of the Lama2(2) muscles. (F: fibula and
T: tibia, showing eosinophils normally present in bone marrow; scale bars: 100 mM). (G) Quantitation of eosinophils in muscle tissues as shown in A–F.
(n=7–13, *p,0.04, **p,0.004). (H) Eotaxin-1 mRNA expression in gastrocnemius/soleus muscles was evaluated by quantitative RT-PCR. Eotaxin-1
was induced in Lama2(2) muscles compared with Lama2(+) controls, but in Lama2(+);MyoD-hBcl-2 muscles, levels were not significantly higher than
Lama2(+) controls. (n=5–8, *p,0.05).
doi:10.1371/journal.pone.0022369.g006
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e22369Of the eight TLRs we examined, only TLR3 was not
significantly induced in Lama2-deficient muscle. TLR3 signaling
is distinct from the other TLRs in that it interacts with the adaptor
protein TRIF rather than the adaptor MyD88 (as do all the other
TLRs) to activate NF-kb pathways and induce cytokine
production [14,27]. TLR4 can also interact with TRIF. It will
be important to determine whether elements of the MyD88-
dependent signaling pathways are involved in the induction of
TLRs observed here. The roles of MyD88, TRIF and other TLR
adaptors in muscle pathogenesis are currently unknown.
The mechanism by which Bcl-2 prevents the induction of
TLR4, TLR6, TLR7, TLR8 and TLR9 is not clear. TLR7, TLR8
and TLR9 are intracellular receptors present on ER membranes
in resting cells and are transported to endosomal membranes when
activated by nucleic acid ligands [28]. TLR4 on the plasma
membrane can also localize to endosomes following ligand
stimulation. Bcl-2 is localized at ER membranes where it reduces
calcium release from the ER under stress conditions [29,30]. Bcl-2
could interact with these intracellular TLR receptors at the ER
membranes, and somehow modulate their synthesis following
activation. TLR4, along with TLR6, is also functional at the
plasma membrane (via endosome-independent pathways), as is
TLR2, whose expression is not significantly affected by Bcl-2, thus
TLR localization does not consistently correlate with Bcl-2 effects
on their mRNA levels. In macrophages and other myeloid
lineages, TLR transcription is regulated by NF-kb [31], IFN-b
[32] or IFN-c [33]. Further studies are required to determine
whether these factors are involved in regulation of TLR mRNAs
in Lama2-deficient muscles, and if their levels or activity are
modulated directly (or indirectly) by Bcl-2.
Multiple functions of Bcl-2 can inhibit cell death mechanisms
[29,30]. A principal Bcl-2 function is to inhibit intrinsic apoptosis
pathways by interacting with pro-apoptotic family members (e.g.
Bax/Bak) at mitochondrial membranes, thereby preventing
mitochondrial outer membrane permeabilization, release of
cytochrome C into the cytoplasm, caspase activation and cell
death. As mentioned, Bcl-2 also localizes to ER membranes
where it can inhibit cellular death mechanisms involving ER
stress and cytotoxic calcium release from the ER. Autophagy can
also be inhibited by Bcl-2 via its interactions with Beclin-1, a Bcl-
2 family member critical for autophagosome formation. Apop-
tosis, ER stress and autophagy can each contribute to muscle
pathogenesis in muscle diseases, including Lama2-deficient and
other congenital muscular dystrophies [34,35,36,37]. Further
studies are thus needed to determine whether one or more of
these mechanisms, or alternatively a novel mechanism, contribute
to induction of TLRs in Lama2-deficient muscle, and to
determine how Bcl-2 expression modulates expression of some
but not all TLRs.
Eosinophils, granulocyte effector cells of innate immunity that
kill damaged cells or foreign pathogens, were also reduced in Bcl-2
transgenic Lama2-deficient muscles compared with non-transgenic
cohorts. TLR2 and TLR7 are mediators of eosinophil activation
and migration [38]. Our observations support the idea that one or
more of these receptors are activated on eosinophils during early
phase of muscle pathology and their chemotaxis can be modulated
as a downstream consequence of muscle-specific Bcl-2 expression,
perhaps via inhibition of eotaxin-1 synthesis. CD11b(+) cell
infiltration was not affected by Bcl-2 in transgenic Lama2-deficient
muscles, therefore only subsets of chemotactic cues might be
modulated by its expression.
A key question yet to be answered is: How is the innate immune
response initiated by the absence of Lama2 indiseased muscles?This
could involve the presence of a variety of DAMP ligands that
activate TLRs leading to the release of IL-1b, TNFa, interferons
and other proinflammatory cytokines. For example, the Lama2-
deficient basal lamina could alter expression of extracellular matrix
ligandsforTLR2andTLR4 suchashyaluronanorfibronectin.The
ligands HMGB1 or HSPs could be leaked through compromised
muscle membranes, as speculated for the innate response observed
in dysferlin-deficient muscle [18,39]. Additionally, intracellular
ligands for TLR3, TLR7, TLR8 and TLR9 such as RNA or DNA
fragments, possibly derived from apoptotic progression, could exist
in Lama2-deficient muscle and promote the initial inflammation.
It will be important to determine the mechanisms responsible
for TLR and NLRP3 gene activation and the nature of TLR
ligands expressed in Lama2-deficient muscle that activate pathways
of innate immunity. Such information could identify novel points
for therapeutic intervention very early in disease progression,
which would be of considerable benefit to patients with this severe
congenital disease.
Supporting Information
Figure S1 Expression of eotaxin-1 in muscle cell cultures.
Proliferating myoblasts or differentiated myotubes were exposed to
the indicated cytokines for 2 or 4 hours then the level of eotaxin-1
mRNA was determined by quantitative RT-PCR. Data is
presented as eotaxin-1 mRNA expression relative to the levels in
a tumorous spleen (T. Spleen) sample, which served as a strong
positive control for this mRNA. Eotaxin-1 was induced in
differentiated myotubes exposed to several cytokines, with IFN-c
(IFN) promoting the strongest response.
(TIF)
Methods S1 Cell Culture and Cytokine Treatments.
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